Zealand Pharma — Maj 2024
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1165660/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Meddelelse: As of 22 May 2024, Polar Capital holds nominally 3,138,798 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 5.01% of the total share capital and total voting rights in Zealand Pharma A/S.
-
-
Polar Capital har således øget antallet af af aktier med 3%.
-
Video: Den Europæiske Centralbank ECB sætter formentlig renten ned i næste uge, men hvor meget? Hør også om NVIDIA, Mærsk og DSV's interesse for at købe DB Schenker, samt om de to danske biotekselskaber Zealand Pharma, Novo Nordisk og Genmab. https://proinvestor.com/boards/120672
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1166285/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Kort video....
Pharma- og biotekopdatering uge 22 | Genmab, Zealand Pharma og Novo Nordisk https://proinvestor.com/boards/120686 -
Spændende om det kan øge interessen i USA:
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 -
Jefferies Global Healthcare Conference, June 4-6 in New York City…….. Goldman Sachs 45th Annual Global Healthcare Conference, June 10-13 in Miami
-
Zealand Pharma: Ekspertpanel anbefaler nødpen udlicenseret til Novo godkendt i EU https://proinvestor.com/investornyt/1166987/zealand-pharma-ekspertpanel-anbefaler-nodpen-udlicenseret-til-novo-godkendt-i-eu
-
Goldman Sachs ser det globale fedmemarked vokse til 130 mia. dollar i 2030 https://proinvestor.com/investornyt/1166978/goldman-sachs-ser-det-globale-fedmemarked-vokse-til-130-mia-dollar-i-2030
-
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
-
Copenhagen, Denmark, May 31, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending granting marketing authorization for dasiglucagon solution for injection in the treatment of severe hypoglycemia in adults, adolescents, and chil
-
"We are very pleased that the European regulatory authorities have recommended approval of dasiglucagon as a rescue treatment for very low blood sugar in people with diabetes," said Adam Steensberg, Chief Executive Officer of Zealand Pharma. "This is an important step in achieving our ambition of bringing this product to many more patients around the world through our partnership with Novo Nordisk, a global leader in diabetes."
-
The positive opinion from the CHMP will be referred to the European Commission (EC) for a final decision whether to grant marketing authorization in the European Union (EU). Zealand expects this decision within approximately three months. Dasiglucagon injection was approved by the U.S. FDA in March 2021 under the brand name Zegalogue
. -
Zealand Pharma: Ekspertpanel anbefaler nødpen udlicenseret til Novo godkendt i EU https://proinvestor.com/investornyt/1167142/zealand-pharma-ekspertpanel-anbefaler-nodpen-udlicenseret-til-novo-godkendt-i-eu
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind